BIO vs LAB
BIO: A multinational life science and clinical diagnostics company providing research tools, diagnostic test systems, and consumables to laboratories and biopharmaceutical manufacturers worldwide. LAB: Standard BioTools provides advanced life science analytical platforms and high-parameter imaging technologies to power discovery in single-cell and spatial biology.
Side-by-side fundamentals
| Metric | BIO | LAB | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $305.96 | $0.82 | |
| Market cap as of 2026-07-23 | $8.2B | $346M | |
| P/E as of 2026-07-23 | 48.82 | 4.43 | LAB lower |
| Net margin as of 2026-07-23 | +6.5% | +90.7% | LAB higher |
| Gross margin as of 2026-07-23 | +51.8% | +49.6% | BIO higher |
| Operating margin as of 2026-07-23 | +2.0% | -111.0% | BIO higher |
| ROE as of 2026-07-23 | +2.4% | +17.3% | LAB higher |
| ROA as of 2026-07-23 | +1.7% | +13.6% | LAB higher |
| Debt / equity as of 2026-07-23 | 0.18 | 0.00 | LAB lower |
| Revenue growth (YoY) as of 2026-07-23 | +1.9% | -49.2% | BIO higher |
| Revenue CAGR (3y) SEC XBRL | -2.7% | -4.5% | BIO higher |
| Beta as of 2026-07-23 | 1.06 | 1.45 | |
| 1-year return as of 2026-07-22 close | +24.6% | -39.8% | BIO higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.